Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)
J. Clin. Oncol 2021 Feb 18;[EPub Ahead of Print], T Cluzeau, M Sebert, R Rahmé, S Cuzzubbo, J Lehmann-Che, I Madelaine, P Peterlin, B Bève, H Attalah, F Chermat, E Miekoutima, OB Rauzy, C Recher, A Stamatoullas, L Willems, E Raffoux, C Berthon, B Quesnel, M Loschi, AF Carpentier, DA Sallman, R Komrokji, A Walter-Petrich, S Chevret, L Ades, P FenauxFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.